Logotipo del repositorio
Logotipo del repositorio
 

Recomendaciones para el manejo del riesgo cardiorrenal en el paciente con diabetes mellitus tipo 2

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_16ecspa
dc.contributor.authorCastillo Barriosa, Gilberto Amed
dc.contributor.authorAroca Martínez, Gustavo
dc.contributor.authorCastillo Barrios, Gilberto Amed
dc.contributor.authorBuelvas Herazo, Jannes
dc.contributor.authorBuitrago S., Andrés F.
dc.contributor.authorCarballo Zárate, Virgil
dc.contributor.authorCárdenas Castellanos, Juan Mauricio
dc.contributor.authorGómez López, Efraín Alonso
dc.contributor.authorFériz Bonelo, Karen
dc.contributor.authorLopera Vargas, John Mauricio
dc.contributor.authorMelgarejo, Enrique
dc.contributor.authorRestrepo Erazo, Katherine
dc.contributor.authorMontejo, Juan Diego
dc.contributor.authorPinzón Barco, Juan Bernardo
dc.contributor.authorQuintero, Adalberto
dc.contributor.authorRico Fontalvo, Jorge E.
dc.contributor.authorRosero R., Ricardo
dc.date.accessioned2020-09-17T17:36:10Z
dc.date.available2020-09-17T17:36:10Z
dc.date.issued2020
dc.description.abstractLos pacientes diabéticos tipo 2 tienen mayor riesgo de desarrollar complicaciones cardiovasculares y renales. La evidencia científica respecto a cómo se debe abordar de manera integral al paciente diabético para prevenir complicaciones cardiorrenales sigue cambiando con rapidez. En los estudios de seguridad cardiovascular los nuevos medicamentos antidiabéticos han demostrado que reducen el desenlace cardiovascular combinado y el deterioro de la función renal. Otros antidiabéticos reducen también el riesgo de hospitalizaciones por insuficiencia cardiaca. Este documento plantea la posición de cuatro sociedades científicas a través de sus expertos delegados, que se encargaron de responder a quince preguntas relacionadas con la prevención y el tratamiento del riesgo cardiorrenal en los pacientes con diabetes mellitus tipo 2.spa
dc.description.abstractPatients with type 2 diabetes mellitus have a higher risk of developing cardiovascular and renal problems. The scientific evidence as regards how this must be approached in the diabetic patient in an integrated manner in order to prevent complications continues changing rapidly. In cardiovascular safety studies, the new anti-diabetic drugs have demonstrated that they reduce the combined cardiovascular outcome and deterioration of kidney function. Other anti-diabetic drugs also the risk of hospital admission due to heart failure. This document sets out the position of four scientific societies through their expert committees, who were also responsible for replying to fifteeneng
dc.format.mimetypepdfspa
dc.identifier.doihttps://doi.org/10.1016/j.rccar.2020.07.005
dc.identifier.issn01205633
dc.identifier.urihttps://hdl.handle.net/20.500.12442/6517
dc.language.isospaspa
dc.publisherSociedad Colombiana de Cardiología & Cirugía Cardiovascularspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacionaleng
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccesseng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceRevista Colombiana de Cardiologíaspa
dc.sourceVol. XX N° XX
dc.subjectDiabetes mellitus tipo 2spa
dc.subjectComplicaciones cardiovascularesspa
dc.subjectEnfermedad renal diabéticaspa
dc.subjectInsuficiencia cardiacaspa
dc.subjectRiesgo cardiovascularspa
dc.subjectType 2 diabetes mellitusspa
dc.subjectCardiovascular complicationseng
dc.subjectDiabetic kidney diseaseeng
dc.subjectHeart failureeng
dc.subjectCardiovascular riskeng
dc.titleRecomendaciones para el manejo del riesgo cardiorrenal en el paciente con diabetes mellitus tipo 2spa
dc.type.driverinfo:eu-repo/semantics/articleeng
dc.type.spaArtículo científicospa
dcterms.referencesInternational Diabetes Federation --- IDF. Diabetes Atlas, 2019. 9th Edition. Publicado en: https://www.diabetesatlas.org.spa
dcterms.referencesBooth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006;368:29---36.eng
dcterms.referencesTancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjörnsdottir S, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720---32.eng
dcterms.referencesLow Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133:2459---502.eng
dcterms.referencesKing RJ, Grant PJ. Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic. Herz. 2016;41:184---92.eng
dcterms.referencesOvbiagele B, Markovic D, Fonarow GC, Recent US. Patterns and Predictors of Prevalent Diabetes among Acute Myocardial Infarction Patients. Cardiol Res Pract. 2011;2011:145615, http://dx.doi.org/10.4061/2011/145615.eng
dcterms.referencesMancini GBJ, Cheng AY, Connelly K, Fitchett D, Goldenberg R, Goodman S, et al. CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. Can J Cardiol. 2018;34:1350---61.eng
dcterms.referencesBloomgarden ZT. Cardiovascular disease and glycemic treatment. Diabetes Care. 2010;33:e134---9.eng
dcterms.referencesCardiovascular Disease, Risk Management:. Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43 Suppl. 1:S111---34, http://dx.doi.org/10.2337/dc20-S010.eng
dcterms.referencesCosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al., 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255---323.eng
dcterms.referencesYoung LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAM. 2009;301:1547---55.eng
dcterms.referencesClerc OF, Fuchs TA, Stehli J, Benz DC, Grani C, Messerli M, et al. Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Imaging. 2018;19:838---46.eng
dcterms.referencesGarber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by The American Association of Clinical Endocrinologist and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm 2020 --- Executive Summary. Endocr Pract. 2020;26:107---39.eng
dcterms.referencesWing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in Type 2 Diabetes. N Engl J Med. 2013;369:145---54.eng
dcterms.referencesGregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, Clark JM, et al., Look AHEAD Research Group. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4:913---21.eng
dcterms.referencesThe Look AHEAD Research Group. Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2014;10:801-9.eng
dcterms.referencesEstruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgen olive oil or nuts. N Engl J Med. 2018;378:e34.eng
dcterms.referencesFacilitating Behavior Change and Well-being to Improve Health Outcomes: Standards of Medical Care in Diabetes- 2020. Diabetes Care. 2020; 43(Suppl. 1):S48-S65. https://doi.org/10.2337/dc20-S005.eng
dcterms.referencesSluik D, Buijsse B, Muckelbauer R, Kaaks R, Teucher B, Fons N, et al. Physical activity and mortality in individuals with diabetes mellitus. A prospective study and meta-analysis. Arch Intern Med. 2012;172:1285.eng
dcterms.referencesPassarella P, Kiseleva T, Valeeva F, Gosmanov A. Hypertension management in diabetes: 2018 Update. Diabetes Spectrum. 2018;31:218---24.eng
dcterms.referencesCushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al., ACCORD Study Group. Effects of intensive control of blood pressure in diabetes mellitus type 2. N Engl J Med. 2010;362:1575---85.eng
dcterms.referencesXie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and metaanalysis. Lancet. 2016;387(10017):435---43.eng
dcterms.referencesEmdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313:603---15.eng
dcterms.referencesSim JJ, Shi J, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol. 2014;64:588---97.eng
dcterms.referencesThomopoulos C, Parati G, Zanchetti A. Effects of bloodpressure- lowering treatment on outcome incidence in hypertension: 10 - Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens. 2017;35:922---44.eng
dcterms.referencesUK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes mellitus (UKPDS 33). Lancet. 1998;352:837-53.eng
dcterms.referencesUK Prospective Diabetes study group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-13.eng
dcterms.referencesBangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123:2799---810.eng
dcterms.referencesWilliams B, Mancia G, Spiering W, Agabati Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021---104.eng
dcterms.referencesTobe SW, Gilbert RE, Jones C, Leiter LA, Prebtani APH, Woo V. Diabetes Canada Clinical Practice Guidelines Expert Committee. Treatment of hypertension. Can J Diabetes. 2018;42 Suppl 1:S186---9.eng
dcterms.referencesFried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892---903.eng
dcterms.referencesArrieta F, Iglesias P, Botet J, Becerra A, Ortega E, Obaya J. Diabetes mellitus y riesgo cardiovascular. Actualización de las recomendaciones del grupo de trabajo de Diabetes y riesgo cardiovascular de la Sociedad Espa˜nola de Cardiología. 2018. Clin Investig Arterioescler. 2018;30:137---53.spa
dcterms.referencesMihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581---90.eng
dcterms.referencesMach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111---88.eng
dcterms.referencesGrundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73:e285---350.eng
dcterms.referencesGiugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, et al. IMPROVE-IT Investigators. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137: 1571---82.eng
dcterms.referencesSabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5:941---50.eng
dcterms.referencesRay KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:618---28.eng
dcterms.referencesKeech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849---61.eng
dcterms.referencesGinsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, et al., ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563---74.eng
dcterms.referencesSaha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus---a pooled meta-analysis of randomized placebo-controlled clinical trials. Int J Cardiol. 2010;141:157---66.eng
dcterms.referencesPradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, et al. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018;206:80---93.eng
dcterms.referencesAung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol. 2018;3: 225---34.eng
dcterms.referencesBhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11---22.eng
dcterms.referencesASCEND Study Collaborative GroupBowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. N Engl J Med. 2018;18:1529---39.eng
dcterms.referencesZheng SL, Roddick AJ. Association of aspirin use for primary prevention. JAMA. 2019;321:277---87 [published correction appears in JAMA. 2019 Jun 11;321(22):2245].eng
dcterms.referencesDavies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2018;61:2461---98.eng
dcterms.referencesBuse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487---93. Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020;43:487---93.eng
dcterms.referencesSchernthaner G, Lehmann R, Prázn´y M, Czupryniak L, Ducena K, Fasching P, et al. Translating recent results from the Cardiovascular Outcomes Trials into clinical practiCE: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). Cardiovasc Diabetol. 2017;16:137, http://dx.doi.org/10.1186/s12933-017-0622-7.eng
dcterms.referencesScirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317---26.eng
dcterms.referencesWhite WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327---35.eng
dcterms.referencesGreen JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232---42.eng
dcterms.referencesRosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321:69---79.spa
dcterms.referencesZinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117---28.eng
dcterms.referencesNeal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in type 2 Diabetes. N Engl J Med. 2017;377:644---57.eng
dcterms.referencesWiviott SD, Raz I, Bonaca MP, Monsenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347---57.eng
dcterms.referencesZelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31---9.eng
dcterms.referencesZelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Furtado RHM, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus systematic review and meta-analysis of cardiovascular outcomes trials. Circulation. 2019;139:2022---31.eng
dcterms.referencesPfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247---57.eng
dcterms.referencesHolman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228---39.eng
dcterms.referencesMarso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311---22.eng
dcterms.referencesMarso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834---44.eng
dcterms.referencesHernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519---29.eng
dcterms.referencesGerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394:121---30.eng
dcterms.referencesHusain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841---51.eng
dcterms.referenceshttps://clinicaltrials.gov/ct2/show/NCT03914326.eng
dcterms.referencesKristensen SL, Rørth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776---85.eng
dcterms.referencesThe ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-28.eng
dcterms.referencesMarso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377:723---32.eng
dcterms.referencesKosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs. The CVD-REAL 2 Study J Am Coll Cardiol. 2018;71:2628---39.eng
dcterms.referencesGlycemic Targets: Standards of Medical Care in Diabetes----2020 American Diabetes Association. Diabetes Care. 2020; 43 (Suppl 1):S66-S76. Disponible en https://doi.org/10.2337/dc20-S006.eng
dcterms.referencesLin YC, Chang YH, Yang SY, Wu KD, Chu TS. Update of pathophysiology and management of diabetic kidney disease. J Formos Med Assoc. 2018;117:662---75.eng
dcterms.referencesSharaf El, Din UAA, Salem MM, Abdulazim DO. Diabetic nephropathy: Time to withhold development and progression - A review. J Adv Res. 2017;8:363---73.eng
dcterms.referencesGorostidi M, Santamaría R, Alcázar R, Fernández-Fresnedo G, Galcerán JM, Goicoechea M, et al. Spanish Society of Nephrology document on KDIGO guidelines for the assessment and treatment of chronic kidney disease. Nefrologia. 2014;34:302---16.eng
dcterms.referencesRadcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig. 2017;8:6---18.eng
dcterms.referencesSarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, et al., SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34:208---30.eng
dcterms.referencesMuskiet MHA, Wheeler DC, Heerspink HJL. New pharmacological strategies for protecting kidney function in type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7:397---412.eng
dcterms.referencesGarcía-Carro C, Vergara A, Agraz I, Jacobs-Cachá C, Espinel E, Seron D, et al. The New era for reno-cardiovascular treatment in type 2 diabetes. J Clin Med. 2019;8, http://dx.doi.org/10.3390/jcm8060864, pii:E864.eng
dcterms.referencesPerkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL. Charytan diabetes mellitus, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295---306.eng
dcterms.referencesNeuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and metaanalysis. Lancet Diabetes Endocrinol. 2019;7:845---54.eng
dcterms.referencesNeuen BL, Jardine MJ, Perkovic V. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future? Nephrol Dial Transplant. 2020;35 Supplement 1:i48---55.eng
dcterms.referencesMann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839---48.eng
dcterms.referencesGerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebocontrolled trial. Lancet. 2019;394:131---8.eng
dcterms.referencesBahtiyar G, Gutterman D, Lebovitz H. Heart failure: a major cardiovascular complication of diabetes mellitus. Curr Diab Rep. 2016;16:116.eng
dcterms.referencesNinˇcevi´c V, Omanovi´c Kolari´c T, Rogulji´c H, Kizivat T, Smoli´c M, Bili´c ´Curˇci´c I. Renal benefits of sglt 2 inhibitors and glp- 1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes. Int J Mol Sci. 2019;20(23.), http://dx.doi.org/10.3390/ijms20235831, pii: E5831.eng
dcterms.referencesHuelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, et al. PONTIAC (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol. 2013;62:1365---72.eng
dcterms.referencesRawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633---44.eng
dcterms.referencesYancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137---61.eng
dcterms.referencesKosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136:249---59.eng
dcterms.referencesVerbrugge FH. Role of SGLT2 Inhibitors in patients with diabetes mellitus and heart failure. Curr Heart Fail Rep. 2017;14:275---83.eng
dcterms.referencesGreene SJ, Butler J. Primary prevention of heart failure in patients with type 2 diabetes mellitus. Circulation. 2019;139:152---4.eng
dcterms.referencesGuglin M, Lynch K, Krischer J. Heart failure as a risk factor for diabetes mellitus. Cardiology. 2014;129:84---92.eng
dcterms.referencesKlajda MD, Scott CG, Rodeheffer RJ, Chen HH. Diabetes mellitus is an independent predictor for the development of heart failure: a population study. May Clin Proc. 2020;95:124---33.eng
dcterms.referencesDunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement from the American Heart Association and the Heart Failure Society of America. Circulation. 2019;140:e294---324.eng
dcterms.referencesGreenberg BH, Abraham WT, Albert NM, Chiswell K, Clare R, Stough WG, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J. 2007;154:277, e1-e277.eng
dcterms.referencesDormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi- Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279---89.eng
dcterms.referencesHome PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125---35.eng
dcterms.referencesScirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579---88.eng
dcterms.referencesCastillo GA, Morales-Villegas E. Tratamiento de la diabetes en el paciente con insuficiencia cardiaca: Más allá de la hemoglobina glicosilada. Rev Colomb Cardiol. 2020;27(S2):33---9, http://dx.doi.org/10.1016/j.rccar.2019.12.004.spa
dcterms.referencesRosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019 Sep 19, http://dx.doi.org/10.1001/jama.2019.13772 [Epub ahead of print].eng
dcterms.referencesMonji A, Mitsui T, Bando YK, Aoyama M, Shigeta T, Murohara T. Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013;305:H295---304.eng
dcterms.referencesRådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, et al. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation. 2018;138:458---68.eng
dcterms.referencesMcMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995---2008.eng
dcterms.referencesPacker M, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, et al. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPERORReduced trial. Eur J Heart Fail. 2019;21:1270---8.eng
dcterms.referencesACCORD Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in Type 2 Diabetes. N Eng J Med. 2008;358:2545-59.eng
dcterms.referencesBonds DE, Miller ME, Bergestal RM, Buse J, Byington R, Cutler J, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study. BMJ. 2010;340:b4909.eng
dcterms.referencesZoungas S, Patel A, Chalmers J, de Galan B, Li Q, Biostat M, et al. Severe hypoglycemia and risks of vascular events and death. ADVANCE Collaborative Group. N Engl J Med. 2010;363:1410---8.eng
dcterms.referencesPieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, et al. DEVOTE 3. Temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia. 2018;61:58---65.eng
dcterms.referencesGoto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013;347:f4533.eng
dcterms.referencesNunes A, Iglay K, Radican L, Engel S, Yang J, Doherty M, et al. Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. Diabetes Obes Metab. 2017;19:1425---35.eng
dcterms.referencesGarg V, Verma S, Connelly K. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes. Prog Cardiovasc Dis. 2019; 62:349---57.eng
dcterms.referencesVerma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108---17.eng
dcterms.referencesMudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPAREG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115---22.eng
dcterms.referencesGarcia-Ropero A, Santos-Gallego CG, Zafar MU, Badimon JJ. Metabolism of the failing heart and the impact of SGLT2 inhibitors. Expert Opin Drug Metab Toxicol. 2019;15: 275---85.eng
dcterms.referencesUthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018;61:722---6.eng
dcterms.referencesHowell R, Wright AM, Clements JN. Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date. Diabetes Metab Syndr Obes. 2019;12:505---12.eng
dcterms.referencesPacker M. Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines. Cardiovasc Diabetol. 2018;17:1---9.eng
dcterms.referencesNauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagonlike peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849---70.eng
dcterms.referencesHeuvelman VD, Van Raalte DH, Smits MM. Cardiovascular effects of GLP-1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res. 2019 Dec 11, pii: cvz323. doi: 10.1093/cvr/cvz323. [Epub ahead of print].eng
oaire.versioninfo:eu-repo/semantics/publishedVersioneng

Archivos

Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca